Key result
Early statin initiation reduces cardiovascular events in ASCVD, while discontinuation worsens outcomes.
Why the study?
Many patients with established atherosclerotic cardiovascular disease remain undertreated and have elevated rates of statin discontinuation, leaving residual cardiovascular risk and potential for severe adverse events from plaque destabilization.
Does early initiation of statin therapy improve cardiovascular outcomes and does discontinuation increase adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease?
Does early initiation of statin therapy improve cardiovascular outcomes and does discontinuation increase adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease?
This review highlights that early initiation and pre-revascularization high-dose statin therapy reduce cardiovascular events in secondary prevention, while statin discontinuation carries significant risk of plaque destabilization and adverse events.
Answers are grounded in this paper and cite their sources.
Supports early statin adherence in ASCVD; leaves open optimal pre-revascularization protocols for prospective trials.
Statins, a class of lipid-lowering drugs, reduce morbidity and mortality in patients with established atherosclerosis-related cardiovascular disease. Early initiation of statin therapy after admission for acute coronary syndromes (ACS), stroke, or transient ischemic attack (TIA) is associated with improved cardiovascular outcomes. Moreover, high-dose statin treatment prior to coronary or carotid revascularization has been shown to reduce cardiovascular events in these patients. However, many patients may be undertreated, and a residual cardiovascular risk remains in current clinical practice. Despite the beneficial role of statins, their discontinuation rate among patients is still elevated leading to severe adverse cardiovascular events due to atherosclerotic plaque destabilization. In this review, we summarized the impact of statin treatment among patients, focusing on the initiation time-points as well as the potential harm derived by their discontinuation.
No takes yet. Share an insight, caveat, or question.
Kadoglou et al. (2021) conducted a review in Atherosclerosis-related cardiovascular disease (including acute coronary syndromes, stroke, or transient ischemic attack). Statin therapy (early initiation, high-dose pretreatment, and discontinuation) was evaluated on Cardiovascular morbidity, mortality, and severe adverse cardiovascular events. Early statin initiation in atherosclerotic cardiovascular disease and pre-revascularization reduces cardiovascular events, whereas discontinuation promotes plaque destabilization and adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: